Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ^*

Kirby John J.

2. Date of Event Requiring Statement (MM/DD/YYYY) 10/31/2018

3. Issuer Name and Ticker or Trading Symbol

IDERA PHARMACEUTICALS, INC. [IDRA]

(Last) (First) (Middle)

C/O IDERA PHARMACEUTICALS, INC., 505 EAGLEVIEW BLVD., SUITE 212

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director _____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below)
V.P. of Finance, PFO & PAO /

(Street)

EXTON, PA 19341

(City) (State) (Zip)

5. If Amendment, Date Original Filed (MM/DD/YYYY)

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2259 ⁽¹⁾	D

*Table II - Derivative Securities Beneficially Owned ( e.g.* , puts, calls, warrants, options, convertible securities)**
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivate Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (Right to Buy)	⁽²⁾ ⁽³⁾	11/2/2025	Common Stock	18750	$24.88	D
Stock Option (Right to Buy)	⁽²⁾ ⁽⁴⁾	1/6/2026	Common Stock	11249	$23.04	D
Stock Option (Right to Buy)	⁽²⁾ ⁽⁵⁾	1/4/2027	Common Stock	12499	$12.72	D
Stock Option (Right to Buy)	⁽²⁾ ⁽⁶⁾	1/3/2028	Common Stock	16874	$17.92	D
Stock Option (Right to Buy)	⁽²⁾ ⁽⁷⁾	8/13/2028	Common Stock	10000	$7.39	D

Explanation of Responses:
(1)	Includes 1,809 shares purchased through the Company's 1995 and 2017 Employee Stock Purchase Plans.
(2)	Option vests over a four-year period commencing on the grant date. 25% vests on the first anniversary date of grant with the balance vesting in equal quarterly installments over the remaining three years of the four-year vesting period.
(3)	Grant date 11/2/15.
(4)	Grant date 1/6/16.
(5)	Grant date 1/4/17.
(6)	Grant date 1/3/18.
(7)	Grant date 8/13/18.

Reporting Owners
Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Kirby John J. C/O IDERA PHARMACEUTICALS, INC. 505 EAGLEVIEW BLVD., SUITE 212 EXTON, PA 19341			V.P. of Finance, PFO & PAO

Signatures
/s/ John J. Kirby		11/2/2018
^** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.